<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01626573</url>
  </required_header>
  <id_info>
    <org_study_id>39110-201</org_study_id>
    <nct_id>NCT01626573</nct_id>
  </id_info>
  <brief_title>A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of INCB039110 in Subjects With Active Rheumatoid Arthritis</brief_title>
  <official_title>A Double- Blind, Placebo Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of INCB039110 in Subjects With Active Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study evaluating a 28-day course followed by a 56-day course of INCB039110 in
      patients with active rheumatoid arthritis (RA). The study will evaluate safety and efficacy
      parameters of INCB039110.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of INCB039110 as assessed by the changes in frequency and severity of adverse events, ECGs, vital signs, physical examinations, and clinical laboratory evaluations.</measure>
    <time_frame>Approximately four months.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Preliminary efficacy as assessed by the percentage of patients achieving ACR20 improvement from baseline on the day 28 and day 84 visits.</measure>
    <time_frame>Approximately 84 days.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preliminary Pharmacokinetic (PK) collections.</measure>
    <time_frame>Following 15 days of therapy.</time_frame>
    <description>Plasma concentrations of INCB039110 will be used to estimate peak plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC).</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>INCB039110 400 mg twice a day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCB039110 400 mg twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INCB039110 400 mg placebo twice a day</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>INCB039110 400 mg placebo twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INCB039110 100 mg twice a day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This dose group will be studied twice during the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INCB039110 100 mg placebo twice a day</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This dose group will be studied twice during the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INCB039110 100mg once a day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCB039110 100mg once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INCB039110 100 mg placebo once a day</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>INCB039110 100 mg placebo once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INCB039110 200 mg twice a day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCB039110 200 mg twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INCB039110 200 mg placebo twice a day</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>INCB039110 200 mg placebo twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INCB039110 300 mg once a day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCB039110 300 mg once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INCB039110 300 mg placebo once a day</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>INCB039110 300 mg placebo once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INCB039110 600 mg once a day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCB039110 600 mg once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INCB039110 600 mg placebo once a day</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>INCB039110 600 mg placebo once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB039110</intervention_name>
    <arm_group_label>INCB039110 400 mg twice a day</arm_group_label>
    <arm_group_label>INCB039110 100 mg twice a day</arm_group_label>
    <arm_group_label>INCB039110 100mg once a day</arm_group_label>
    <arm_group_label>INCB039110 200 mg twice a day</arm_group_label>
    <arm_group_label>INCB039110 300 mg once a day</arm_group_label>
    <arm_group_label>INCB039110 600 mg once a day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB039110 Placebo</intervention_name>
    <arm_group_label>INCB039110 400 mg placebo twice a day</arm_group_label>
    <arm_group_label>INCB039110 100 mg placebo twice a day</arm_group_label>
    <arm_group_label>INCB039110 100 mg placebo once a day</arm_group_label>
    <arm_group_label>INCB039110 200 mg placebo twice a day</arm_group_label>
    <arm_group_label>INCB039110 300 mg placebo once a day</arm_group_label>
    <arm_group_label>INCB039110 600 mg placebo once a day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with active RA aged 18 to 75 years of age and meet tender and swollen joint
             assessment expectations defined in the study protocol.

          -  c-Reactive protein (CRP) or erythrocyte sedimentation rate (ESR) laboratory values
             meet minimal study protocol expectations.

        Exclusion Criteria:

          -  Females who are pregnant or breastfeeding.

          -  Men and women who cannot comply with requirements to avoid fathering a child or
             becoming pregnant, respectively.

          -  Subjects treated with a biologic agent within 12 weeks prior to first dose of study
             drug. (12 months in the case of rituximab.)

          -  Subjects with a history or currently suspected inflammatory disease other than RA.

          -  Subjects with a history of hematological disorders.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Victor Sandor, MD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lake Mary</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tavares</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Worchester</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Florence</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Carolina</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2012</study_first_submitted>
  <study_first_submitted_qc>June 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2012</study_first_posted>
  <disposition_first_submitted>March 26, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>March 26, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 22, 2014</disposition_first_posted>
  <last_update_submitted>March 26, 2014</last_update_submitted>
  <last_update_submitted_qc>March 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>RA</keyword>
  <keyword>Active</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

